Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Medical Sciences Business Development & Partnering Team are delighted to announce that the AIMday in Advanced Therapies & Regenerative Medicine is now open for registration by academics.

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? 

If you answer YES to any of the above, now is the time to register for the AIMday in Advanced Therapies & Regenerative Medicine, taking place on Wednesday 3 April at the Blavatnik School of Government. A range of companies including LIft Biosciences, Alcyomics, Oxford MEStar, Novo Nordisk, DJS Antibodies, The Electrospinning Company and Bio-Techne are registered to attend, and it will be a fantastic opportunity for researchers looking to network with industry and discuss relevant questions. To see the questions posed by these companies, please visit aimday.se/atrm-2019/questions-listing.

This years AIMday follows on from previous successful AIMdays in Ageing (2016), Microscopy (2017) and Biomedical Imaging (2018).

FREE registration for academics is now open and closes on 15 March. 

Please note, advance registration is essential

To register and find out more, please visit aimday.se/ATRM-2019

What are AIMdays?

  • AIMdays provide a platform for companies to host roundtable discussions with a group of self-selecting academics
  • Industry sets the agenda and topics for discussion
  • Academics from across multiple disciplines sign up to participate in the discussions

How does it work?

Step 1: Companies submit a question/s around the theme of the day

Step 2: Oxford’s researchers sign up to answer one or more of the questions

Step 3: One question, one hour for discussion, one group of experts

 

For additional information please contact amira.burshan@medsci.ox.ac.uk

Find out more about the work of the Business Development & Partnering Team

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.

Oxford-led technology to help those at high risk from Covid-19

Coronavirus COVID-19 General Research

More people in England at high risk from Covid-19 will get priority access to vaccines thanks to new technology developed by a University of Oxford-led team of researchers that can identify those who may be most vulnerable to the virus.